Thermalin Company
Thermalin hopes to disrupt the $30B insulin/insulin delivery market with a disposable, postage-stamp-sized glucose management system enabled by our first-in-class stabilized, highly concentrated, and ultra-rapid acting insulin. This same new insulin molecule in "ordinary" (U-100) concentration will enable the factory-filling of reservoirs for existing insulin pumps. In addition to this lead program, Thermalin is developing partnerships on no-cold-chain basal and mix insulins and on glucose-responsive insulins.
Industry:
PharmTech
Headquarters:
Cleveland, Ohio, United States
Zip:
11-50
Founded Date:
2010-01-01
Employees Number:
11-50
Acquisitions Number:
6
Investors Number:
37624859
Total Funding:
$1M to $10M
Estimated Revenue:
$1M to $10M
Last Funding Date:
Convertible Note
Last Funding Type:
rick@thermalin.com
Register and Claim Ownership